| How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease? | |
| | |
MedLine Citation:
|
PMID: 20613629 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
An increasing number of patients in the community are being treated with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and beta-blockers for hypertension, coronary disease or diabetic renal and vascular complications. Some of these patients will develop heart failure despite such treatment. Based on data from hypertension trials it can be estimated that approximately 5% of treated patients will develop heart failure over 5 years. It is unclear whether patients developing heart failure on and off ACE-inhibitors or beta-blockers, respectively, at the time of heart failure diagnosis have similar prognosis.Treatment options for patients developing heart failure while already treated with ACE inhibitors/ARBs and beta-blockers are very limited if current heart failure guidelines are followed. In this review possible strategies are outlined and important areas for research are identified. It is suggested that trials are designed specifically to address prognosis and treatment in this growing population. |
| | |
Authors:
|
Finn Gustafsson; Julian Segura; Luis M Ruilope |
Related Documents
:
|
22100929 - Effect of right ventricular pacing site on qrs width. 21738449 - Cardiac complications in patients with community-acquired pneumonia: a systematic revie... 22577429 - Chlamydia pneumoniae infection and cardiac risk factors in patients with myocardial inf... 22394459 - Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patie... 22560269 - A case of spontaneous coronary artery dissection: it is not always plaque rupture. 22110019 - Galectin-3 and the development of heart failure after acute coronary syndrome: pilot ex... 16390019 - Cold infarction areas of varying size in the presence of left ventricular dysfunction: ... 12417359 - Stroke vs. chronic progressive cerebrovascular disease: a magnetic resonance imaging st... 18376199 - Ascending and transverse aortic arch repair: the impact of glomerular filtration rate o... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of hypertension Volume: 28 ISSN: 1473-5598 ISO Abbreviation: J. Hypertens. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-21 Completed Date: 2010-11-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8306882 Medline TA: J Hypertens Country: England |
Other Details:
|
Languages: eng Pagination: 1595-8 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, University of Copenhagen, Denmark bHypertension Unit, Hospital 12 de Octubre, Rigshospitalet, Madrid, Spain. finng@dadlnet.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use* Angiotensin II Type 1 Receptor Blockers / therapeutic use* Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Coronary Artery Disease / complications, diagnosis, drug therapy* Diabetes Complications / diagnosis, prevention & control* Disease Progression Heart Failure / etiology, prevention & control* Humans Hypertension / complications, diagnosis, drug therapy* Prognosis Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experiment...
Next Document: Neuroretinitis with retrobulbar involvement.